PTC Therapeutics | PTCT - Current Assets

Stock Price
70.42
Daily Change
-0.24 -0.34%
Monthly
-7.62%
Yearly
40.78%
Q1 Forecast
68.47

PTC Therapeutics reported $2.27B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
BioCryst Pharmaceuticals USD 355.68M 42.78M Sep/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
TG Therapeutics USD 599.76M 64.2M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xencor USD 518.44M 5.29M Sep/2025